Researcher Profile

Researcher Profile

Patrick Chi-Chung Ma, MD, MSc

Patrick Chi-Chung Ma, MD, MSc

Professor, Department of Medicine
Scientific Program:Next-Generation Therapies
pcm5221@psu.edu

Research Interests

  • Therapeutics
  • Neoplasms
  • Non-Small Cell Lung Carcinoma
  • Lung Neoplasms
  • Mutation
  • Small Cell Lung Carcinoma
  • Hepatocyte Growth Factor
  • ErbB Receptors
  • Neoplasm Metastasis
  • Protein-Tyrosine Kinases
  • Erlotinib Hydrochloride
  • Adenocarcinoma of Lung

Clinical Trials

APG-115 - A Phase Ib/II Study of APG-115 in Combination with Pembrolizumab in Patients with Unresectable or Metastatic Melanomas or Advanced Solid Tumors
Phase 1/2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Medically Inoperable Stages I or IIA Non Small Cell Lung Cancer (NSCLC)(KEYNOTE-867) MK 3475-867
A Phase III Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib, Compared to Concurrent Chemoradiation Therapy Followed by Placebo in Participants with Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK7339-013)
A Phase I/II Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C mutation (MRT849-001)
Phase II, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer
A randomized phase II trial of adjuvant Pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153
A Phase II Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy Versus Placebo with Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC) CX-839-014
NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study
S1827 A randomized Phase III trial comparing prophylactic cranial irradiation (PCI) for any patient with small cell lung cancer (either extensive or limited stage) to active surveillance with MRI in place of PCI
A Phase II Study of Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select IIIA [T3N1, T4N0-1] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA) Big Ten Cancer Research Consortium BTCRC-LUN19-396
NRG-LU007 Randomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

Recent Publications

2021

Mattes, MD, Eubank, TD, Almubarak, M, Wen, S, Marano, GD, Jacobson, GM & Ma, PC 2021, 'A Prospective Trial Evaluating the Safety and Systemic Response From the Concurrent Use of Radiation Therapy with Checkpoint Inhibitor Immunotherapy in Metastatic Non–Small Cell Lung Cancer', Clinical Lung Cancer, vol. 22, no. 4, pp. 268-273. https://doi.org/10.1016/j.cllc.2021.01.012
Albandar, HJ, Fuqua, J, Albandar, JM, Safi, S, Merrill, SA & Ma, PC 2021, 'Immune-related adverse events (Irae) in cancer immune checkpoint inhibitors (ici) and survival outcomes correlation: To rechallenge or not?', Cancers, vol. 13, no. 5, 989, pp. 1-15. https://doi.org/10.3390/cancers13050989
Lee, M, Jain, P, Wang, F, Ma, PC, Borczuk, A & Halmos, B 2021, 'MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies', Expert Opinion on Therapeutic Targets, vol. 25, no. 4, pp. 249-268. https://doi.org/10.1080/14728222.2021.1925648

2020

Attia, CG, Fei, N, Almubarak, M, Ma, PC & Mattes, MD 2020, 'Patterns of disease progression to checkpoint inhibitor immunotherapy in patients with stage IV non-small cell lung cancer', Journal of Medical Imaging and Radiation Oncology, vol. 64, no. 6, pp. 866-872. https://doi.org/10.1111/1754-9485.13096
Kizilbash, SH, El-Khoueiry, A, Lerner, RE, Ma, PC, Almubarak, M, Mody, K, Burkard, ME, Guarino, M, Jenab-Wolcott, J, Sankar, N, Choy, G, Espiritu, L, Zhang, X, Luria, A, Benedetti, F & Dees, EC 2020, 'Phase 1/2 study of the safety and efficacy of APL-101, a specific c-MET inhibitor', European Journal of Cancer, vol. 138, pp. S11-S12. https://doi.org/10.1016/S0959-8049(20)31095-9
Brownmiller, T, Juric, JA, Ivey, AD, Harvey, BM, Westemeier, ES, Winters, MT, Stevens, AM, Stanley, AN, Hayes, KE, Sprowls, SA, Gatesman Ammer, AS, Walker, M, Bey, EA, Wu, X, Lim, ZF, Zhu, L, Wen, S, Hu, G, Ma, PC & Martinez, I 2020, 'Y chromosome LncRNA are involved in radiation response of male non-small cell lung cancer cells', Cancer Research, vol. 80, no. 19, pp. 4046-4057. https://doi.org/10.1158/0008-5472.CAN-19-4032

2019

Ma, PC 2019, '(Not giving up) the marathon race of Met targeting therapy: Are we there yet?', Clinical Cancer Research, vol. 25, no. 8, pp. 2375-2378. https://doi.org/10.1158/1078-0432.CCR-18-3739
Jonna, S, Feldman, RA, Swensen, J, Gatalica, Z, Korn, WM, Borghaei, H, Ma, PC, Nieva, JJ, Spira, AI, Vanderwalde, AM, Wozniak, AJ, Kim, ES & Liu, SV 2019, 'Detection of NRG1 gene fusions in solid tumors', Clinical Cancer Research, vol. 25, no. 16, pp. 4966-4972. https://doi.org/10.1158/1078-0432.CCR-19-0160
Lim, ZF & Ma, PC 2019, 'Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy', Journal of Hematology and Oncology, vol. 12, no. 1, 134. https://doi.org/10.1186/s13045-019-0818-2
Chen, R, Xia, W, Wang, S, Xu, Y, Ma, Z, Xu, W, Zhang, E, Wang, J, Fang, T, Zhang, Q, Dong, G, Cho, WCS, Ma, PC, Brandi, G, Tavolari, S, Ujhazy, P, Metro, G, Popper, HH, Yin, R, Qiu, M & Xu, L 2019, 'Long Noncoding RNA SBF2-AS1 Is Critical for Tumorigenesis of Early-Stage Lung Adenocarcinoma', Molecular Therapy - Nucleic Acids, vol. 16, pp. 543-553. https://doi.org/10.1016/j.omtn.2019.04.004
Ahmad, Z, Stanazai, Q, Wright, S, Smolkin, M & Ma, PC 2019, 'Primary pleural epithelioid sarcoma of the proximal type: A diagnostic and therapeutic challenge', Translational Lung Cancer Research, vol. 8, no. 5, pp. 700-705. https://doi.org/10.21037/tlcr.2019.09.16
Morgensztern, D, Rose, M, Waqar, SN, Morris, J, Ma, PC, Reid, T, Brzezniak, CE, Zeman, KG, Padmanabhan, A, Hirth, JA, I. Spira, A, Trepel, JB & Padda, SK 2019, 'RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer', British Journal of Cancer, vol. 121, no. 3, pp. 211-217. https://doi.org/10.1038/s41416-019-0504-8
Kibirova, A, Mattes, MD, Smolkin, M & Ma, PC 2019, 'The Journey of an EGFR-Mutant Lung Adenocarcinoma through Erlotinib, Osimertinib and ABCP Immunotherapy Regimens: Sensitivity and Resistance', Case Reports in Oncology, vol. 12, no. 3, pp. 765-776. https://doi.org/10.1159/000503417

2018

Drilon, A, Laetsch, TW, Kummar, S, Dubois, SG, Lassen, UN, Demetri, GD, Nathenson, M, Doebele, RC, Farago, AF, Pappo, AS, Turpin, B, Dowlati, A, Brose, MS, Mascarenhas, L, Federman, N, Berlin, J, El-Deiry, WS, Baik, C, Deeken, J, Boni, V, Nagasubramanian, R, Taylor, M, Rudzinski, ER, Meric-Bernstam, F, Sohal, DPS, Ma, PC, Raez, LE, Hechtman, JF, Benayed, R, Ladanyi, M, Tuch, BB, Ebata, K, Cruickshank, S, Ku, NC, Cox, MC, Hawkins, DS, Hong, DS & Hyman, DM 2018, 'Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children', New England Journal of Medicine, vol. 378, no. 8, pp. 731-739. https://doi.org/10.1056/NEJMoa1714448
Oronsky, B, Ma, P, Reid, TR, Cabrales, P, Lybeck, M, Oronsky, A, Oronsky, N & Carter, CA 2018, 'Navigating the “No Man's Land” of TKI-Failed EGFR-Mutated Non–Small Cell Lung Cancer (NSCLC): A Review', Neoplasia (United States), vol. 20, no. 1, pp. 92-98. https://doi.org/10.1016/j.neo.2017.11.001
Wu, X, Zhu, L & Ma, PC 2018, 'Next-Generation Novel Noninvasive Cancer Molecular Diagnostics Platforms Beyond Tissues', American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, no. 38, pp. 964-977. https://doi.org/10.1200/EDBK_199767

2017

Wu, X, Ma, W, Zhou, Q, Yan, H, Lim, ZF, Huang, M, Deng, C, Yu, X, Su, H, Komo, S, Yang, H, Zhang, X, Wen, S, Zhang, Z & Ma, PC 2017, 'AXL–GAS6 expression can predict for adverse prognosis in non-small cell lung cancer with brain metastases', Journal of Cancer Research and Clinical Oncology, vol. 143, no. 10, pp. 1947-1957. https://doi.org/10.1007/s00432-017-2408-4
Chaib, I, Karachaliou, N, Pilotto, S, Codony Servat, J, Cai, X, Li, X, Drozdowskyj, A, Servat, CC, Yang, J, Hu, C, Cardona, AF, Vivanco, GL, Vergnenegre, A, Sanchez, JM, Provencio, M, de Marinis, F, Passaro, A, Cao, P, Reguart, N, Campelo, CG, Teixido, C, Sperduti, I, Rodriguez, S, Lazzari, C, Verlicchi, A, de Aguirre, I, Queralt, C, Wei, J, Estrada, R, de la Bellacasa, RP, Ramirez, JL, Jacobsen, K, Ditzel, HJ, Santarpia, M, Viteri, S, Molina, MA, Zhou, C, Cao, P, Ma, PC, Bivona, TG & Rosell, R 2017, 'Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC', Journal of the National Cancer Institute, vol. 109, no. 9. https://doi.org/10.1093/jnci/djx014
Boothe, JT, Budd, GT, Smolkin, MB & Ma, PC 2017, 'Durable near-complete response to Anti-PD-1 checkpoint immunotherapy in a refractory malignant solitary fibrous tumor of the pleura', Case Reports in Oncology, vol. 10, no. 3, pp. 998-1005. https://doi.org/10.1159/000484041
Oronsky, B, Ma, PC, Morgensztern, D & Carter, CA 2017, 'Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas', Neoplasia (United States), vol. 19, no. 12, pp. 991-1002. https://doi.org/10.1016/j.neo.2017.09.002
Ma, PC 2017, 'Special issue: "MET as actionable target in cancer therapy"', Annals of Translational Medicine, vol. 5, no. 1, 1. https://doi.org/10.21037/atm.2017.01.10
Pilotto, S, Carbognin, L, Karachaliou, N, Ma, PC, Rosell, R, Tortora, G & Bria, E 2017, 'Tracking MET de-addiction in lung cancer: A road towards the oncogenic target', Cancer Treatment Reviews, vol. 60, pp. 1-11. https://doi.org/10.1016/j.ctrv.2017.08.002
Guo, T, Zhao, S, Wang, P, Xue, X, Zhang, Y, Yang, M, Li, N, Li, Z, Xu, L, Jiang, L, Zhao, L, Ma, PC, Rosell, R, Li, J & Gu, C 2017, 'YB-1 regulates tumor growth by promoting MACC1/c-Met pathway in human lung adenocarcinoma', Oncotarget, vol. 8, no. 29, pp. 48110-48125. https://doi.org/10.18632/oncotarget.18262

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)